UNSPSC 51411706: Vinburnine

This classification denotes a vasodilator agent with the molecular formula C19H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G54D0HMY25, chemically known as 14,15-dihydroeburnamenin-14-one but generally known as vinburnine, which bears US NIH Compound Identifier 3195. European Medicines Agency schedules Vinburnine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00053MIG. World Health Organization schedules vinburnine in its Anatomical Therapeutic Chemical (ATC) Classification.

UNSPSC 51411706 Vinburnine, a Commodity code, covers pharmaceutical active ingredients and finished medications procured by state and local health agencies, emergency medical services, and cooperative purchasing alliances for clinical use. State and local governments buy under this code to stock emergency medications, maintain pharmacy benefit programs, and supply hospital and fire rescue operations. Issuing bodies include city purchasing departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope ranges from individual medication line items for emergency response (such as advanced life support injectables for fire rescue) to bulk generic pharmaceutical contracts serving multiple participating jurisdictions through authorized wholesalers.

Recent activity appears concentrated in the South and Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated value $40,000) requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue; the contract carries a one-year term with two optional one-year renewals plus three additional 30-day extension periods at the City's discretion, and includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awarded contracts effective July 1, 2026 and a two-year term. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs supporting the state's pharmacy benefit operations outside traditional pharmacy benefit manager arrangements.